Article Text

Download PDFPDF

401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
  1. Manish Sharma1,
  2. Ecaterina Ileana Dumbrava2,
  3. Richard Carvajal3,
  4. Daniel Catenacci4,
  5. Leisha Emens5,
  6. Glenn Hanna6,
  7. Dejan Juric7,
  8. Yoon-Koo Kang8,
  9. Jeeyun Lee9,
  10. Keun-Wook Lee10,
  11. Bob Li11,
  12. Kathleen Moore12,
  13. Mark Pegram13,
  14. Paula Pohlmann14,
  15. Drew Rasco15,
  16. Alexander Spira16,
  17. Antoinette Tan17,
  18. Ding Wang18,
  19. Shelley Ackerman19,
  20. Heidi LeBlanc19,
  21. David Dornan19,
  22. Marcin Kowanetz19,
  23. Michael Alonso19,
  24. Edith Perez19 and
  25. Edith Perez19
  1. 1START Midwest, Grand Rapids, MI, USA
  2. 2The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  3. 3Columbia University Medical Center, New York, NY, USA
  4. 4University of Chicago, Chicago, IL, USA
  5. 5UPMC Hillman Cancer Center, Pittsburgh, PA, USA
  6. 6Dana-Farber Cancer Institute, Boston, MA, USA
  7. 7Massachusetts General Hospital, Boston, MA, USA
  8. 8Asan Medical Center, Seoul, Korea, Republic of
  9. 9Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of
  10. 10Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
  11. 11Memorial Sloan Kettering Cancer Center, New York, NY, USA
  12. 12Stephenson Cancer Center, Oklahoma City, OK, USA
  13. 13Stanford University, Stanford, CA, USA
  14. 14Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
  15. 15START, San Antonio, TX, USA
  16. 16Virginia Cancer Specialists, Fairfax, VA, USA
  17. 17Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
  18. 18Henry Ford Cancer Institute/Henry Ford Hospital, Detroit, MI, USA
  19. 19Bolt Biotherapeutics, Redwood City, CA, USA


Background In spite of advances made in the management of patients with HER2-expressing or -driven solid tumors, there remains a significant unmet need for novel approaches to improve patient outcomes. Intratumoral delivery of antitumor antibodies and immunostimulatory adjuvants such as toll-like receptor (TLR)7/8 agonists has been shown to activate tumor resident antigen-presenting cells (APCs), driving uptake, processing, and presentation of tumor neoantigens to T cells that mediate antitumor immunity. BDC-1001 is delivered systemically and has demonstrated superior preclinical biology. This novel ISAC consists of an investigational biosimilar of the humanized monoclonal antibody trastuzumab chemically conjugated to a TLR7/8 agonist with a non-cleavable linker. BDC-1001 activates human myeloid APCs in addition to retaining antibody-mediated effector functions such as antibody-dependent cellular cytotoxicity/phagocytosis (ADCC/ADCP). Studies in trastuzumab-resistant xenograft models and syngeneic tumor models indicate that HER2-targeted ISACs elicit potent and durable immune-mediated antitumor efficacy, leading to complete tumor regression in a TLR- and Fc receptor-dependent manner.1 2 Importantly, BDC-1001 did not induce interstitial lung disease, cytokine release syndrome, or thrombocytopenia in non-human primate studies. A four-part phase 1/2, first-in-human study has been initiated that evaluates BDC-1001 with or without (±) an immune checkpoint inhibitor targeting PD-1 in patients with HER2-expressing or HER2-amplified advanced/metastatic solid tumors.

Methods This dose-escalation and dose-expansion study is enrolling up to 390 patients with HER2-expressing (IHC2+ or 3+ protein, irrespective of gene amplification) or HER2-amplified (by in situ hybridization or next-generation sequencing) advanced solid tumors. Primary objectives of the dose-escalation phase are to define safety and tolerability and determine the recommended phase 2 dose of BDC-1001 as monotherapy (Part 1) and in combination with an immune checkpoint inhibitor (Part 2). Part 2 is planned to start once BDC-1001 safety data are available. Primary endpoints include incidence of 1) adverse events and serious adverse events; 2) dose-limiting toxicities within a 3+3 design; and 3) potential immune-related toxicities. The dose-expansion portion of the trial will evaluate preliminary antitumor activity of BDC-1001 alone (Part 3) and in combination with an immune checkpoint inhibitor (Part 4). Secondary objectives will evaluate pharmacokinetic parameters and pharmacodynamic biomarkers in tumor tissue and in peripheral blood associated with drug exposure. These exploratory studies will help elucidate the mechanism of action and seek to identify biomarkers associated with BDC-1001 biological activity with or without immune checkpoint inhibitor. This global study is currently recruiting patients.

Results N/A

Conclusions N/A

Trial Registration ClinicalTrials. gov (NCT04278144).

Ethics Approval The study and the protocol were or will be approved by the Institutional Review Board or ethics committee at each site.

Consent N/A


  1. Ackerman, et al. TLR7/8 immune-stimulating antibody conjugates elicit robust myeloid activation leading to enhanced effector function and anti-tumor immunity in pre-clinical models. Cancer Res. 2019:79 [13 Suppl]:Abstract 1559.

  2. Ackerman, et al. HER2-targeting TLR7/8 immune-stimulating antibody conjugates elicit robust myeloid activation and anti-tumor immune responses in a TLR- and FcR- dependent manner. J Immunother Cancer 2019;7:283

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.